Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Napabucasin - Boston Biomedical

Drug Profile

Napabucasin - Boston Biomedical

Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A; GB-201

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Biomedical
  • Developer 1Globe Biomedical; Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Furans; Naphthoquinones; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Phase I/II Gastrointestinal cancer; Glioblastoma; Liver cancer; Mesothelioma; Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 25 Oct 2018 Phase-III clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03721744)
  • 01 Oct 2018 1Globe Biomedical plans a phase III trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO) (NCT03721744)
  • 03 Aug 2018 Phase-I development in Haematological malignancies (Late-stage disease, Second-line therapy or greater) is ongoing in USA (PO) (NCT02352558)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top